• Home
  • Search Results
  • Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate.

Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate.

The Journal of steroid biochemistry and molecular biology (2015-05-11)
Frank Giton, Nanor Sirab, Grégory Franck, Marianne Gervais, Fabien Schmidlin, Tauhid Ali, Yves Allory, Alexandre de la Taille, Francis Vacherot, Sylvain Loric, Jean Fiet

High plasma exposure to estrogens is often associated with prostate cancer. Reducing this phenomenon may present therapeutic benefits. The involvement of estrone sulphate (E1S), the most abundant circulating estrogen in men, has been partially studied in this age-related pathology. To investigate the consequences of plasma E1S overload on blood and prostate sex steroid levels and inflammatory tissue responses, young and middle-aged male rats were treated with E1S with or without steroid sulfatase (STS) inhibitor STX64 for 21 consecutive days. A plasma and prostate tissue steroid profile was determined. STS activity, mRNA expression of E1S organic anion transporting polypeptides (slco1a2, slco2b1, slco4a1) and pro-inflammatory cytokines (Il1-beta, Il6, TNF-alpha) were evaluated in prostate tissue according to age and treatment group. A significant correlation between plasma and prostate steroid levels related to hormone treatment was observed in all rat age groups. However, while the E1S level in prostate tissue increased in middle-aged treated rats (p<0.0001), no significant variation was observed in young treated rats. The protective effect of STX64 during E1S infusion was observed by the maintenance of low free estrogen concentrations in both plasma and tissue. However, this protection was not associated with mRNA expression stability of pro-inflammatory cytokines in older rat prostate. These results suggest that E1S uptake in rat prostate cells increases during aging. Therefore, if a similar phenomenon existed in men, preventively reducing the STS activity could be of interest to limit uptake of estrogens in prostate when high E1S plasma level is assayed.

Product Number
Product Description

2,2,4-三甲基戊烷, anhydrous, 99.8%
二喹啉甲酸 二钠盐 水合物, ≥98% (HPLC)
2,3,4,5,6-五氟苯甲酰氯, 99%
甲基纤维素, viscosity: 25 cP
Estrone 3-sulfate sodium salt, contains ~35% Tris as stabilizer
STX64, ≥98% (HPLC)